mitoxantrone has been researched along with Leukemia, Prolymphocytic, B-Cell in 1 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Leukemia, Prolymphocytic, B-Cell: A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tempescul, A | 1 |
| Feuerbach, J | 1 |
| Ianotto, JC | 1 |
| Dalbies, F | 1 |
| Marion, V | 1 |
| Le Bris, MJ | 1 |
| De Braekeleer, M | 1 |
| Berthou, C | 1 |
1 other study available for mitoxantrone and Leukemia, Prolymphocytic, B-Cell
| Article | Year |
|---|---|
A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |